Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Major Depression, Anhedonia, Melancholic...
Phase NA
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn if the proposed intermittent theta burst stimulation (iTBS) protocol can effectively improve anhedonia symptoms in depressed patients. The stimulation targets in our protocol include (1) dual-target stimulation at the left dorsolateral prefrontal cortex (DLPFC) and orbitofrontal cortex (OFC). (2) single-target stimulation at the left DLPFC. The main questions it aims to answer are: * Whether iTBS of dual-target stimulation (left DLPFC and OFC) can improve the symptoms of anhedonia and better than single-target stimulation at the left DLPFC? * Whether iTBS of the dual targets of left DLPFC and OFC can improve the symptoms of anhedonia by correcting the abnormal functional connectivity of DLPFC-NAc and OFC-sgACC, regulating the functional abnormalities of NAc and sgACC, and indirectly repairing the overall dysfunction of the reward circuit. * Researchers will compare dual-target stimulation to single-target stimulation and sham dual-target stimulation (a dedicated sham coil is utilized which produces an identical audible click and physical sensation) to see if the proposed iTBS protocol works to treat anhedonia. Participants will: * Take 6 sessions of dual-target iTBS or single-target iTBS every day, for 5 consecutive days. * Visit our hospital at 1 week, 4 weeks, and 8weeks after the iTBS treatment completion, for clinical evaluation and brain image examination.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Left DLPFC + OFC iTBS — iTBS Parameter Specifications: 60 cycles of 10 bursts of three pulses at 50 Hz were delivered in 2-second trains (5 Hz) with an 8-second intertrain interval. The total duration of a single session is 10 minutes, comprising 60 trains and yielding a total of 1,800 pulses per session. For the Left DLPFC + OFC iTBS Group, stimulation is first delivered to the left DLPFC-NAc functional region using the specified iTBS parameters (1,800 pulses per session), performed 3 sessions daily with a 50-minute interval between sessions. Subsequently, stimulation is applied to the left OFC-sgACC functional region with the identical parameters (1,800 pulses per session), also performed 3 sessions daily with a 50-minute interval. This yields a cumulative total of 10,800 pulses over 5 consecutive days, for a total of 54,000 pulses.
  • Device: Left DLPFC iTBS — iTBS Parameter Specifications: 60 cycles of 10 bursts of three pulses at 50 Hz were delivered in 2-second trains (5 Hz) with an 8-second intertrain interval. The total duration of a single session is 10 minutes, comprising 60 trains and yielding a total of 1,800 pulses per session. For the left DLPFC iTBS Group, stimulation is delivered solely to the left DLPFC-NAc functional region using the specified iTBS parameters, with 6 sessions performed daily, each with a 50-minute interval between sessions. This yields a cumulative total of 10,800 pulses over 5 consecutive days, for a total of 54,000 pulses.

Primary Outcomes

  • Total score of Montgomery-Åsberg Depression Rating Scale (MADRS) (*Baseline; * Day 2- Day 6 (every treatment day); *1 week post-treatment; *4 weeks post-treatment; *8 weeks post-treatment.)
  • Remission Rate of Montgomery-Åsberg Depression Rating Scale (MADRS) scores (* Day 2- Day 6 (every treatment day); *1 week post-treatment; *4 weeks post-treatment; *8 weeks post-treatment.)
  • Response Rate of Montgomery-Åsberg Depression Rating Scale (MADRS) scores (* Day 2- Day 6 (every treatment day); *1 week post-treatment; *4 weeks post-treatment; *8 weeks post-treatment.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-05-19
Completion: 2027-07-03
Eligibility
Age: 18 Years – 45 Years
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Guo Wenbin
Principal Investigators:
  • Wenbin Guo, PhD (PRINCIPAL_INVESTIGATOR) - Second Xiangya Hospital of Central South University
Contact Information
Study Contact:
Wenbin Guo, PhD
+86 73185360921
guowenbin76@csu.edu.cn
Meiqi Yan, Master
+86 18155517736
meiqi7012@163.com
The Second Xiangya Hospital of Central South University
Interventions
  • Device: Left DLPFC + OFC iTBS — iTBS Parameter Specifications: 60 cycles of 10 bursts of three pulses at 50 Hz were delivered in 2-second trains (5 Hz) with an 8-second intertrain interval. The total duration of a single session is 10 minutes, comprising 60 trains and yielding a total of 1,800 pulses per session. For the Left DLPFC + OFC iTBS Group, stimulation is first delivered to the left DLPFC-NAc functional region using the specified iTBS parameters (1,800 pulses per session), performed 3 sessions daily with a 50-minute interval between sessions. Subsequently, stimulation is applied to the left OFC-sgACC functional region with the identical parameters (1,800 pulses per session), also performed 3 sessions daily with a 50-minute interval. This yields a cumulative total of 10,800 pulses over 5 consecutive days, for a total of 54,000 pulses.
  • Device: Left DLPFC iTBS — iTBS Parameter Specifications: 60 cycles of 10 bursts of three pulses at 50 Hz were delivered in 2-second trains (5 Hz) with an 8-second intertrain interval. The total duration of a single session is 10 minutes, comprising 60 trains and yielding a total of 1,800 pulses per session. For the left DLPFC iTBS Group, stimulation is delivered solely to the left DLPFC-NAc functional region using the specified iTBS parameters, with 6 sessions performed daily, each with a 50-minute interval between sessions. This yields a cumulative total of 10,800 pulses over 5 consecutive days, for a total of 54,000 pulses.
Study Locations (1 sites)
The Second Xiangya Hospital of Central South University, Changsha, Hunan 410000 China
Eligibility Criteria
Inclusion Criteria: 1. Aged 18-45 years, and right-handed; 2. Diagnosed with major depressive disorder (MDD) by at least two qualified psychiatrists, according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), with a Montgomery-Åsberg Depression Rating Scale (MADRS) score ≥ 20 or a 17-item Hamilton Depression Rating Scale (HAMD-17) score ≥ 17; 3. Evaluated by a psychiatrist as having prominent anhedonia, and meeting the cutoff criteria on two self-report anhedonia scales, including a Snaith-Hamilton Pleasure Scale, Chinese version (SHAPS-C) score ≥ 20, or a Temporal Experience of Pleasure Scale, Chinese version (TEPS-C) score ≤ 76; 4. Medication type and dosage remained unchanged for at least 4 weeks prior to treatment initiation and throughout the study period; 5. MADRS item 10 score ≤ 4. Exclusion Criteria: 1. A history of epilepsy, seizures, stroke, or other serious organic brain diseases; 2. Presence of severe infectious diseases, malignant tumors, or other major unstable medical conditions; 3. Intellectual disability or developmental delay, presence of psychotic symptoms, or meeting the diagnostic criteria for other psychiatric disorders; 4. A history of substance abuse or psychoactive substance use; 5. Presence of intracranial implants (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes), or any other metallic objects in or near the head that cannot be safely removed (excluding dental fillings); 6. Contraindications to MRI or structural intracranial abnormalities detected on MRI; 7. Pregnant or breastfeeding women; 8. Receipt of electroconvulsive therapy (ECT) within the past 6 months, or transcranial magnetic stimulation (TMS) within the past 3 months; 9. Current daily use of lorazepam \> 2 mg (or an equivalent dose), or use of antiepileptic drugs at any dose; 10. Presence of strong suicidal ideation, or a MADRS item 10 score \> 4.
Conditions Bipolar Depression
Phase NA
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

The aim of this study is to evaluate the feasibility and efficacy of deep transcranial magnetic stimulation (dTMS) as an add-on treatment for bipolar depression. Meanwhile, we aim to evaluate the effect of dTMS on cognitive function of bipolar depressive patients. We hypothesize dTMS would improve depressive symptoms and cognitive function in bipolar disorder.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Device: deep Transcranial Magnetic Stimulation (dTMS) -active — with the H1-coil device included 20-min sessions of 18 Hz (2-s trains separated by 20-s inter-train intervals, 55 trains totaling 1980 pulses/session).
  • Device: deep Transcranial Magnetic Stimulation (dTMS) -sham — The sham stimulation was performed using the same procedures, with the sham coil.

Primary Outcomes

  • The change over time in the score of Hamilton Depression Rating Scale (HDRS-17). (baseline, week 2, week 4, week 8)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-08-01
Completion: 2026-02
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Tianjin Anding Hospital
Contact Information
Study Contact:
Jie Li, Doctor
+86 022 88188006
jieli@tjmhc.com
Jie Li, Doctor
+86 022 88188006
jieli@tjmhc.com
Tianjin Anding Hospital
Interventions
  • Device: deep Transcranial Magnetic Stimulation (dTMS) -active — with the H1-coil device included 20-min sessions of 18 Hz (2-s trains separated by 20-s inter-train intervals, 55 trains totaling 1980 pulses/session).
  • Device: deep Transcranial Magnetic Stimulation (dTMS) -sham — The sham stimulation was performed using the same procedures, with the sham coil.
Study Locations (1 sites)
Tianjin Anding Hospital, Tianjin, China
Eligibility Criteria
Inclusion Criteria: Confirmed diagnosis of bipolar depression; * age between 18 and 65 years; * a 17-item Hamilton Depression Rating Scale (HDRS-17) score \>= 17, * a stable pharmacological regimen maintained for at least 4 weeks prior to the beginning of the treatment phase ; * for participants who had previously received antidepressant therapy, a minimum 4-week washout period followed by re-evaluation. Exclusion Criteria: * a lifetime history of other psychiatric disorders, neurological diseases, or severe brain injury; * receipt of electroconvulsive therapy, rTMS, transcranial direct current stimulation, transcranial alternating current stimulation, or other neurostimulation treatments within the previous 3 months; * contraindications to magnetic stimulation, including epilepsy, cardiovascular disorders, or metallic implants in the head; * the presence of hypomanic/manic symptoms at baseline or a score greater than 12 on the Young Mania Rating Scale (YMRS); * pregnancy or lactation.
Conditions Bipolar Depression
Phase NA
Enrollment 10
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

Bipolar disorder (BD) affects between 1-3% of the world's population. People with BD experience episodes of mania or hypomania and in most cases, they experience periods of depression which can cause difficulties in daily life. Psychological therapies for people experiencing depression without mania or hypomania are widely available, but there is little research into how effective these therapies are for people with BD. Behavioral activation therapy (BA) is based on behavioral theory and has been proven to be an effective treatment for unipolar depression. It helps people re-establish healthier activity patterns and sleep regulation, especially in BD for mood stabilization. BA is theoretically and clinically well matched to the treatment of bipolar depression, but there is still very little research into offering BA to people with BD. The first aim of the current research is to implement BA for people with depression in Bipolar Disorder and study if it is feasible for this patient group. The second aim is to do a pilot study on the effectiveness of the treatment for this patient group. The research will be implemented with people seeking treatment at the specialized service for bipolar disorder at Landspítali University Hospital in Iceland. The participants will receive treatment as usual and the BA will be adjunctive. At least ten people, that are currently experiencing Bipolar Depression and are willing to take part, will receive up to 20 individual therapy sessions of BA that have been adapted for Bipolar Depression (BA-BD), and will complete regular questionnaires and interviews. The study will be a replication study to validate the previous study's findings by Kim, W. et al., 2022 in another setting.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Behavioural Activation (BA) — BA is based on the assumption that depression may be precipitated and is maintained by a reduction in "healthy", adaptive behaviours and positive reinforcement of these, and an increase in avoidance behaviours. Together, these changes reduce the person's immediate distress, often at the expense of their medium and longer term goals. The therapy involves helping the individual to re-establish healthy patterns of activity, and replace avoidance behaviours with more adaptive behaviours that are constructive in the longer term. The intervention consists of up to 20 individual therapy sessions of Behavioural Activation, with one booster session three months after the end of therapy. Each session lasts approximately 50 minutes and this is supplemented by home practice between sessions.

Primary Outcomes

  • Minimally clinically significant improvement in depression symptoms for a majority of participants (>60%) (through study completion, an average of 7 months)
  • Therapy uptake rate (through study completion, an average of 7 months)
  • Therapy completion rate (through study completion, an average of 7 months)
  • Change in activity levels as measured by consumer connected health devices (through study completion, an average of 7 months)
  • Change in Sleep Duration measured by health device (through study completion, an average of 7 months)
  • No significant adverse reaction for participants (through study completion, an average of 7 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-11-22
Completion: 2025-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 10 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Reykjavik University
Collaborators: Landspitali University Hospital
Principal Investigators:
  • Brynja B Magnúsdóttir, PhD (STUDY_CHAIR) - Reykjavik University
  • Anna S Islind, PhD (PRINCIPAL_INVESTIGATOR) - Reykjavik University
  • Steinunn G Sigurðardóttir, MSc (PRINCIPAL_INVESTIGATOR) - Reykjavik University
Contact Information
Study Contact:
Halla Ó Ólafsdóttir, Cand. psych
8688371
hallaosh@landspitali.is
Brynja Bj Magnúsdóttir, PhD
8489685
brynjabm@ru.is
Halla Ó Ólafsdóttir, Cand. psych
003548688371
hallaosh@landspitali.is
Landspitali university hospital
Interventions
  • Behavioral: Behavioural Activation (BA) — BA is based on the assumption that depression may be precipitated and is maintained by a reduction in "healthy", adaptive behaviours and positive reinforcement of these, and an increase in avoidance behaviours. Together, these changes reduce the person's immediate distress, often at the expense of their medium and longer term goals. The therapy involves helping the individual to re-establish healthy patterns of activity, and replace avoidance behaviours with more adaptive behaviours that are constructive in the longer term. The intervention consists of up to 20 individual therapy sessions of Behavioural Activation, with one booster session three months after the end of therapy. Each session lasts approximately 50 minutes and this is supplemented by home practice between sessions.
Study Locations (1 sites)
Landspitali university hospital, Reykjavik, 101 Iceland
Eligibility Criteria
Inclusion Criteria: * scoring in the clinical range on a self-report measure of depression severity (the PHQ-9) meeting diagnostic criteria for depression based on a diagnosis on Diagnostic Interview for Anxiety, Mood, and OCD and Related Neuropsychiatric Disorders (DIAMOND) meeting diagnostic criteria for Bipolar I or II Disorder DIAMOND) participants will require a working knowledge of written and spoken Icelandic, sufficient to make use of therapy and complete research assessments without the need for a translator. Exclusion Criteria: * current/past learning disability, organic brain change, substance dependence (drugs and alcohol) that would compromise the ability to use therapy * current marked risk to self (i.e., self-harm or suicide) that we deem could not be appropriately managed in the Bipolar outpatient clinic at Landspitali. * currently lacking the capacity to give informed consent * currently receiving other psychosocial therapy for depression or bipolar disorder * presence of another area of difficulty that the therapist and client believe should be the primary focus of intervention (for example, Post-Traumatic Stress Disorder, psychosis)
Conditions Type 2 Diabetes, High Blood Pressure
Phase PHASE1, PHASE2
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

This study will investigate the utility of a polypill-based strategy for patients with type 2 diabetes mellitus and high risk of heart failure (HF), as assessed via the WATCH-DM risk score. Polypill therapy will consist of empagliflozin 12.5 mg, losartan 25, 50 or 100 mg, and finerenone 10 mg daily. The study duration is 6 months, and participants will be randomized to either polypill therapy or simultaneous prescription of the individual drugs. The primary outcome is change in peak VO2 and adherence to usual care. The investigators hypothesize that the use of a polypill is feasible and improves medication adherence and peak VO2 as compared to those receiving usual care.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Randomized Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Polypill — A combination of finerenone 10 mg, empagliflozin 12.5 mg, and losartan 50 mg or 100 mg within a polycapsule.
  • Drug: Combined prescription of the individual medications — We will initiate participants on an ARB, SGLT2i, and Finerenone if they are not in the polypill arm.

Primary Outcomes

  • Oxygen uptake during peak exercise (Peak VO2) (Baseline, 3-month, and 6-month)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2024-03-11
Completion: 2027-12-01
Eligibility
Age: 18 Years – 100 Years
Sex: ALL
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Texas Southwestern Medical Center
Principal Investigators:
  • Ambarish Pandey, MD, MSCS (PRINCIPAL_INVESTIGATOR) - UT Southwestern
Contact Information
Study Contact:
Ambarish Pandey, MD, MSCS
214-645-2101
ambarish.pandey@utsouthwestern.edu
Ambarish Pandey, MD
214-645-9762
ambarish.pandey@utsouthwestern.edu
UT Southwestern Medical Center
Interventions
  • Drug: Polypill — A combination of finerenone 10 mg, empagliflozin 12.5 mg, and losartan 50 mg or 100 mg within a polycapsule.
  • Drug: Combined prescription of the individual medications — We will initiate participants on an ARB, SGLT2i, and Finerenone if they are not in the polypill arm.
Study Locations (1 sites)
UT Southwestern Medical Center, Dallas, Texas 75235 United States
Eligibility Criteria
Inclusion Criteria: * Patients with Type 2 DM * History of chronic kidney disease, defined as an estimated glomerular filtration rate (eGFR) of 25 to 90 per minute per 1.73 m2 of body-surface area (stage 2 to 4 CKD) with a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of less than 5000 * With either a: High risk of HF as defined by High Watch-DM score (≥11) or Elevated natriuretic peptides or Diastolic dysfunction or left ventricular hypertrophy on echocardiography Exclusion Criteria: * eGFR \< 25 * Congestive heart failure * Hyperkalemia \> 5.0 * Contraindication to any component of polypill * Pregnancy * Creatinine \>2.0mg/dL in men and \>1.8mg/dL in women * Inability to calculate WATCH-DM score * Inability to undergo exercise testing
Conditions Visual Field Defect, Peripheral
Phase NA
Enrollment 1000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to test a new way of measuring the peripheral vision (called a visual field test) using a device which can be worn as goggles rather than being a large instrument the patient must sit at. This new visual field test (called VisuALL) is an FDA-approved virtual reality system which has been used in adults and children. This study will compare the performance of the VisuALL to the standard testing for peripheral vision, which is called the Humphrey Visual Field (HVF) test. The study will recruit both healthy children, as well children and young adults who have eye conditions which require visual field testing as part of their standard care. The test will be performed on a day when the child or young adult already has a scheduled eye appointment as standard care. The test does not touch the eyes or require any eye drops to be given, and there is no known risk associated with the test itself. There may be a risk of loss of confidentiality. Participating in this study will require approximately 30 minutes, has no extra cost associated with it, and will be compensated by a parking pass for the day of the visit. There are no direct benefits for participants. Selected participants will be also be given training and then loaned a home VisuALL system to allow home visual field testing. If your child is selected, additional information would be provided.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Device: VisuALL — Virtual Reality Visual Field Device
  • Device: Humphrey Visual Field — Standard of care Visual Field test

Primary Outcomes

  • Mean deviation results of visual field parameters (During office visit, approximately 30 minutes)
  • Pattern standard deviation results of visual field parameters (During office visit, approximately 30 minutes)
  • Sensitivity results of visual field parameters (During office visit, approximately 30 minutes)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-01-19
Completion: 2028-07-01
Eligibility
Age: 4 Years – 21 Years
Sex: ALL
Volunteers: true
Enrollment: 1000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Duke University
Principal Investigators:
  • Sharon F Freedman, MD (PRINCIPAL_INVESTIGATOR) - Duke University
Contact Information
Study Contact:
Sharon F Freedman, MD
(919) 681-3937
sharon.freedman@duke.edu
Nikita Piryani, MD
2624081232
nikita.piryani@duke.edu
Duke University Medical Center
Interventions
  • Device: VisuALL — Virtual Reality Visual Field Device
  • Device: Humphrey Visual Field — Standard of care Visual Field test
Study Locations (1 sites)
Duke University Medical Center, Durham, North Carolina 27705 United States
Eligibility Criteria
Inclusion Criteria: * Patients must be at least four (4) years old * Cognitively normal (no developmental delay or syndrome) * Be able to tolerate wearing the virtual reality goggles for at least 10 minutes * Be able to provide informed consent of a parent/guardian (and assent if 12 years or older) * Do not have any ocular diseases that could interfere with the visual field testing Exclusion Criteria: * Developmental delay * Inability to obtain consent * Inability to understand English
Conditions Endometrial Cancer, Genetic Predispositi...
Phase Not Applicable
Enrollment 280
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

Endometrial cancer (EC) is one of the most prevalent cancers in women worldwide with a significantly increasing incidence, especially in developed countries. One of the reasons for the increase in the incidence of this disease is the rising incidence of obesity as the biggest risk factor for the development of this disease. Other important risk factors are hypertension, diabetes mellitus and the general ageing of the population. These risk factors are not only associated with a higher risk of developing the disease, but also, for example, with post-operative complications affecting the quality of life of patients after surgery. The molecular classification of endometrial cancer, which has been introduced into clinical practice in recent years, is currently helping physicians to make treatment decisions for individual patients and predict prognosis. In this project, we would like to focus on the relationship of this molecular classification with genomic mutational signatures detected by whole-exome sequencing and their association with lifestyle risk factors for endometrial cancer (obesity - BMI, hypertension, diabetes mellitus), including the extent of staging lymphadenectomy. Identification and detailed analysis of dominant mutational profiles associated with a specific molecular subtype of EC and their influence on the presence of lifestyle risk factors may have a major impact on both disease development and prevention of disease recurrence. The possible relationship of the mutational profile with the extent of staging lymphadenectomy may help in deciding the extent of this surgical procedure, which subsequently affects the quality of life of patients, especially in patients with high BMI. Given the widespread prevalence of lifestyle risk factors in the developed world, a detailed understanding of the relationship between the genetic profile, its alterations and the prevalence of these risk factors, with potentially major implications for treatment success, is crutial.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Genetic variants/mutation signatures (Sampled during surgery)
  • Quality of life of EC patients using the EORTC QLQ-C30 questionnaire (Questionnaires filled before surgery, then after 6,12,24 months)
  • Quality of life of EC patients using the EORTC QLQ-EN24 questionnaire (Questionnaires filled before surgery, then after 6,12,24 months)
  • Physical activity of EC patients (Questionnaires filled before surgery, then after 6,12,24 months)
  • Introduction of methodology of ctDNA detection by digital PCR of consecutive follow-up samples. (Collection of blood samples at the day of surgery, then after 6,12 and 24 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-07-15
Completion: 2028-12
Eligibility
Age: Not reported
Sex: FEMALE
Volunteers: false
Enrollment: 280 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Lukas Vanek
Collaborators: National Institute of Public Health, Czech Republic
Principal Investigators:
  • Michael Halaška, prof. MUDr. (PRINCIPAL_INVESTIGATOR) - Medical director
Contact Information
Study Contact:
Michael Halaška, prof. MUDr.
+420 296472368
michael.halaska@fnkv.cz
Věra Štěpánková
+42026716 2739
vera.stepankova@fnkv.cz
Michael Halaška, prof. MUDr.
+420 296472368
michael.halaska@fnkv.cz
Faculty Hospital Královské Vinohrady
Interventions
N/A
Study Locations (1 sites)
Faculty Hospital Královské Vinohrady, Prague, Czechia
Eligibility Criteria
Inclusion Criteria: * Clinical diagnosis of endometrial cancer. * Treated with uterine removal with adequate staging. Exclusion Criteria: * There are no exclusion criteria in this study.
Conditions Portal Hypertension, Cirrhosis, Varices,...
Phase Not Applicable
Enrollment 375
Locations 8 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

This multicentre, prospective cohort study aims to enrol 375 patients with cirrhosis who meet the following criteria: 1. effective management or elimination of the primary aetiological factor (i.e., sustained virological response in chronic hepatitis C, complete viral suppression in chronic hepatitis B, or long-term alcohol abstinence in alcohol-related liver disease), 2. liver stiffness measurements under 25 kPa, and 3. absence of varices as confirmed by endoscopy Following the cessation of non-selective beta-blockers, patients will undergo a follow-up endoscopy at the one-year mark. The study's primary endpoint is recurrent varices in 1 year. Success will be defined as the upper bound of the 95% confidence interval for recurrent varices being \<5%. Should this criterion be met, the study will extend to predefined analyses of variceal haemorrhage and hepatic decompensation at 3-and 10-year intervals (funded through local resources; the General Research Fund will cover patient recruitment costs for 1 year). Clinical assessments, laboratory tests, liver and spleen stiffness measurements will be performed at baseline, 3 months, 6 months and 12 months to identify potential predictors of variceal recurrence and assess the feasibility of early identification.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Recurrent varices (1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-01-20
Completion: 2031-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: Not specified
Enrollment: 375 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Chinese University of Hong Kong
Collaborators: Southern Medical University, China, Ruijin Hospital, National University Hospital, Singapore, Changi General Hospital, Institute of Liver and Biliary Sciences, India, Royal Prince Alfred Hospital, Sydney, Australia, Asian Institute of Gastroenterology, India
Principal Investigators:
  • Vincent Wong, MD (PRINCIPAL_INVESTIGATOR) - Chinese University of Hong Kong
Contact Information
Study Contact:
Vincent Wong, MD
85235051299
wongv@cuhk.edu.hk
Angel Chim, MSc
85235054205
angelchim@cuhk.edu.hk
Ken Liu, PhD
61-295156111
Ken.Liu@health.nsw.gov.au
Royal Prince Alfred Hospital
Interventions
N/A
Study Locations (8 sites)
Royal Prince Alfred Hospital, Sydney, Australia
Southern Medical University, Guangzhou, China
Ruijing Hospital, Shanghai, China
Prince of Wales Hospital, Hong Kong, Hong Kong
AIG Hospital, Hyderabad, India
Institute of Liver and Biliary Sciences, New Delhi, India
Changi General Hospital, Singapore, Singapore
National University Hospital, Singapore, Singapore, Singapore
Eligibility Criteria
Inclusion Criteria: * Aged 18 years or above * Evidence of cirrhosis, based on either radiological and/or clinical features * History of varices, variceal haemorrhage or portal hypertension warranting NSBB * Removal or suppression of the primary aetiological factor (i.e., sustained virological response in chronic hepatitis C, complete hepatitis B virus DNA suppression in chronic hepatitis B, and long-term alcohol abstinence in alcohol-related liver disease) * LSM \<25 kPa * Provision of written informed consent Exclusion Criteria: * Active aetiological factors not addressed in the inclusion criteria (e.g., autoimmune or hereditary liver diseases). However, hepatic steatosis-commonly coexisting with other liver diseases-is not an exclusion criterion unless accompanied by high plasma alanine aminotransferase \>40 U/L or confirmed steatohepatitis. * Recent hepatic decompensation within the past year (total bilirubin \>50 μmol/L, prothrombin time \>1.3 times the upper normal limit \[unless attributable to use of anti-coagulation\], albumin \<35 g/L, or presence of ascites, variceal haemorrhage or hepatic encephalopathy). Notably, the Baveno VI criteria used LSM \<20-25 kPa and normal platelet count \>150×109/L to rule out varices requiring treatment (19). However, in line with the Baveno VII consensus, which sets an LSM \<25 kPa as the threshold for considering NSBB discontinuation, thrombocytopenia is not an exclusion criterion to allow the cohort to include a wider spectrum of patients. * Current or history of hepatocellular carcinoma. * Radiological evidence of portal vein thrombosis. * History of other malignancies (unless in complete remission for \>5 years). * History of liver transplantation or liver resection. * Contraindications to undergoing endoscopy. * Other clinical indications for NSBB (e.g., cardiovascular disease, arterial hypertension)
Conditions Hypertension, CKD - Chronic Kidney Disea...
Phase NA
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

The study aims to study the effects of diatery nitrate in patients with hypertension and hypertensive kidney injury. The study is a randomized, placebo-controlled, double-blinded crossover trial. 14-20 patients with hypertension and CKD I-III will be randomized to receive either nitrate or placebo delivered in the form of beetroot juice. Effect variables will be measured before and after a 2 week treatment. After a washout period of 14 days, the subjects are crossed over to the opposite treatment. The study is terminated by measuring effect variables after the second treatment period.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Dietary Supplement: Beetroot Juice - Active — Intervention is beetroot juice ("Beet It concentrated beetroot juice shots", James White Drinks Ltd, Ipswich, England) The nitrate content of the juice is standardized. The dose of nitrate will be 70 ml/day corresponding to intake of 6.5 mmol/400 mg of nitrate.
  • Dietary Supplement: Beetroot juice placebo — The placebo beetroot juice is a corresponding nitrate free beetroot juice, obtained from the manufacturer ("Beet It nitrate depleted shots", James White Drinks Ltd, Ipswich, England.). The placebo juice appears identical to the nitrate containing juice regarding color and taste.

Primary Outcomes

  • Changes in 24 h systolic blood pressure (Measured on day 1 and day 15 of the intervention period (This represents baseline and after conclusion of each intervention period))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-12-08
Completion: 2030-01-01
Eligibility
Age: 18 Years – 70 Years
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Gødstrup Hospital
Contact Information
Study Contact:
Kezia T McWhan, MD
004578436580
kezmcw@rm.dk
Kezia T McWhan, MD
004578432390
kezmcw@rm.dk
University Clinic in Nephrology and Hypertension, Gødstrup Regional Hospital and Aarhus University
Interventions
  • Dietary Supplement: Beetroot Juice - Active — Intervention is beetroot juice ("Beet It concentrated beetroot juice shots", James White Drinks Ltd, Ipswich, England) The nitrate content of the juice is standardized. The dose of nitrate will be 70 ml/day corresponding to intake of 6.5 mmol/400 mg of nitrate.
  • Dietary Supplement: Beetroot juice placebo — The placebo beetroot juice is a corresponding nitrate free beetroot juice, obtained from the manufacturer ("Beet It nitrate depleted shots", James White Drinks Ltd, Ipswich, England.). The placebo juice appears identical to the nitrate containing juice regarding color and taste.
Study Locations (1 sites)
University Clinic in Nephrology and Hypertension, Gødstrup Regional Hospital and Aarhus University, Herning, 7400 Denmark
Eligibility Criteria
Inclusion Criteria: * Hypertension, treated with a maximum of 2 antihypertensive drugs and unattended office BP \< 150/95 mmHg at the screening visit, or newly diagnosed without antihypertensive treatment by 24-hour BP or home BP measurement (above 130/80 or 135/85 respectively), and unattended office BP \< 160/100 mmHg. * CKD I-III based on hypertensive kidney injury. Patients, who previously met the criteria for CKD I within the last 5 years, but no longer has proteinuria after relevant treatment, can also be included. Diagnosis of CKD I can be based on eGFR and either urine albumin/creatine ration or urine-dipstick test with presence of protein. * Albumin/creatinine ratio \< 500 mg/g * eGFR \> 30 ml/min/1,73m2 * Body Mass Index (BMI) ≤ 35 kg/m2 * Able to adhere to dietary regimen * Fertile women must use safe contraception (oral contraceptive pill, hormonal or copper intrauterine device, vaginal ring, contraceptive implant, transdermal contraceptive patch or contraceptive injections) or abstinence. Excluded from this are postmenopausal woman without menstrual bleeding for at least 12 months before inclusion, surgically sterilized women and women with surgically sterilized partner. Exclusion Criteria: * • Diagnosis of heart failure, NYHA II-IV * Diagnosis of liver failure * Diabetes mellitus (all types) * Current malignant disease (other than non-melanoma skin cancer) * Indicators of other aetiologies of CKD than hypertensive kidney injury, e.g. through kidney biopsy or biochemistry. * Previous kidney transplant recipient * History of stroke or transient cerebral ischemic attack * Current indication of untreated cardiovascular disease, e.g. planned work-up for ischemia. * History of myocardial infarction, apart from non-STEMI more than 1 year prior to the study, if the subject is currently revascularized and relevantly medicated. Organic nitrate treatment Diagnosed secondary hypertension other than renal parenchymal hypertension (i.e. renal artery stenosis, primary hyperaldosteronism, low renin hypertension etc.) * Pregnancy or lactation * Alcohol abuse (intake above the recommended guidelines from Danish Health Authorities) * Conditions treated with medication that investigator finds may interfere with the effect parameters, and cannot be discontinued during the trial (e.g. atrial fibrillation treated with betablockers) * If, according to the investigator's assessment, the participant is considered unsuitable to participate.
Conditions Breast Cancer
Phase Not Applicable
Enrollment 600
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

In this multicenter retrospective cohort study the aim is to determine the safety of omission of axillary lymph node dissection in patients with TNBC and HER2+ tumors with residual macrometastases (in the SLN/TAD/TAS or MARI node) after NAC.

Design

Study type: Observational Observational model: Cohort Time perspective: Retrospective

Interventions / Regimen

  • Other: Data Collection from medical records of from an already existing database "ONCOLOGICAL BREAST SURGERY DATABASE OF THE UNIVERSITY HOSPITAL OF BASEL" which was initiated in 2016. — All trial data are/ have been collected within the clinical routine between 2013 and October 2024. All data will be analyzed descriptively using adequate statistical measures and plots. Clinico-pathological characteristics will be compared between patients treated with and without ALND. Depending on the median follow-up of both cohorts (ALND, no ALND) the 3-year cumulative incidence rates will be compared between ALND and no ALND.

Primary Outcomes

  • 3-year rate of any axillary recurrence (3-year follow-up after diagnosis of stage I-III TNBC or HER2+ breast cancer and SLN surgery/TAD/TAS/MARI)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-02-01
Completion: 2027-12
Eligibility
Age: Not reported
Sex: ALL
Volunteers: false
Enrollment: 600 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital, Basel, Switzerland
Principal Investigators:
  • Walter P. Weber, Prof. Dr. med. (PRINCIPAL_INVESTIGATOR) - Department Breast, Abdomen, Pelvis
  • Giacomo Montagna, MD MPH (STUDY_DIRECTOR) - Breast Service, Department of Surgery; Memorial Sloan Kettering Cancer Center
Contact Information
Study Contact:
Walter P. Weber, Prof. Dr. med.
+41 61 328 61 49
walter.weber@usb.ch
Andy Schneider, PhD
+41 61 328 42 98
andy.schneider@usb.ch
Walter P. Weber, Prof. Dr. med.
+41 61 328 61 49
walter.weber@usb.ch
Department Breast, Abdomen, Pelvis; Universitätsspital Basel
Interventions
  • Other: Data Collection from medical records of from an already existing database "ONCOLOGICAL BREAST SURGERY DATABASE OF THE UNIVERSITY HOSPITAL OF BASEL" which was initiated in 2016. — All trial data are/ have been collected within the clinical routine between 2013 and October 2024. All data will be analyzed descriptively using adequate statistical measures and plots. Clinico-pathological characteristics will be compared between patients treated with and without ALND. Depending on the median follow-up of both cohorts (ALND, no ALND) the 3-year cumulative incidence rates will be compared between ALND and no ALND.
Study Locations (1 sites)
Department Breast, Abdomen, Pelvis; Universitätsspital Basel, Basel, 4031 Switzerland
Eligibility Criteria
Inclusion Criteria: * Women and men with a diagnosis of stage I-III TNBC or HER2+ breast cancer at diagnosis. HER2+ is defined as an Immunohistochemistry (IHC) score of 3+ or positive FISH. TNBC is defined as ER and Progesterone Receptor (PR) IHC expression of 0 and HER2 negativity defined as either IHC expression of 0-1+ or lack of gene amplification (FISH \< 2.0). Patients with ER low (1-10%) and/or PR low (1-10%) tumors are allowed. * Any histological subtype * For Clinical Nodal Stage (cN) 0 at presentation: any axillary staging technique including palpation with or without imaging is allowed. Dual tracer mapping is not required for SLN surgery. * For cN+ at presentation: Percutaneous biopsy proven confirmation is required at diagnosis. Staging techniques after NAC include: SLN surgery with dual mapping or Targeted Axillary Dissection (TAD: imaging-guided localization of sampled node in combination with SLN procedure with or without dual mapping) or Tailored Axillary Surgery (TAS: removal of the sentinel lymph nodes as well as selective removal of all palpable disease and documentation of the removal of the initially biopsy-proven and clipped lymph node metastasis by specimen radiography) or the MARI procedure (Marking Axillary Lymph Nodes with Iodine Seeds). * Received neoadjuvant chemotherapy * Residual macrometastases (metastasis greater than 2 mm in diameter) detected on SLN surgery or TAD ot TAS or MARI (on frozen section or final pathology) * Concomitant presence of Isolated Tumor Cells (ITCs) and micrometastases in other sentinel lymph nodes is allowed * Following SLN surgery/TAD/TAS/MARI patients underwent completion ALND, nodal radiation therapy (RT), both or no further axillary treatment * At least 1-year follow-up (had surgery at any time point until October 2024 at the latest) - Prior history of ductal carcinoma in situ (DCIS) is allowed Exclusion Criteria: * Did not undergo SLN surgery/TAD/TAS/MARI (e.g., went straight to ALND) * Presence of ITCs or micrometastases alone in the sentinel nodes (or TAD nodes or MARI node or TAS nodes) without macrometastases * HR+HER2- tumors (except ER low and or PR-low) * Stage IV disease at presentation * Inflammatory breast cancer at presentation * Neoadjuvant endocrine therapy * Macrometastases detected by Oncoplastic Breast Consortium (OSNA)

Protein Needs Study

NCT04144907
Recruiting
Conditions Colorectal Cancer, Breast Cancer
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

Severe muscle loss in patients with cancer has been associated with increased physical disability, extended hospitalization, infectious and noninfectious complications, increased risk of severe toxicity during cancer treatment, poor quality of life and shortened survival. Adequate protein is key to sustain muscle mass and overall health. However, current nutritional recommendations are not specific or evidence-based. The aim of this project is to determine the protein needs of patients with colorectal or breast cancer. Protein needs will be determined using a novel, non-invasive approach. Our results will inform nutritional recommendations and guidelines with the ultimate goal of improving outcomes for people with cancer.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Dietary Supplement: Phenylalanine intake — Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein-free cookies and 4 labeled amino acid experimental meals.

Primary Outcomes

  • 13C Phenylalanine Oxidation (8.5 hours)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2021-04-26
Completion: 2030-09-30
Eligibility
Age: 45 Years – 80 Years
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Alberta
Principal Investigators:
  • Carla Prado, PhD, RD (PRINCIPAL_INVESTIGATOR) - University of Alberta
Contact Information
Study Contact:
Barbara Chaves Santos, PhD
780-492-7820
barbara.santos@ualberta.ca
Anne Caretero, RD
780-492-7820
caretero@ualberta.ca
University of Alberta
Interventions
  • Dietary Supplement: Phenylalanine intake — Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein-free cookies and 4 labeled amino acid experimental meals.
Study Locations (1 sites)
University of Alberta, Edmonton, Alberta T6G 2R3 Canada
Eligibility Criteria
Inclusion Criteria: * Outpatients age 45-80 years; * Patients attending the new patient clinic at the Cross Cancer Institute with a diagnosis of colorectal cancer or breast cancer (stages II to III); * Able to complete baseline visits within approximately 4 weeks of starting chemotherapy OR after a minimum of 4 weeks post-surgery if not undergoing chemotherapy; * Ambulatory. Exclusion Criteria: * Premenopausal women due to impact on protein requirements; * Received anti-cancer hormone treatment or immunotherapy in the 4 weeks before first baseline visit; * Renal impairment based on a creatinine clearance for estimated glomerular filtration rate (eGFR) of \<60 mL/min * Abnormal glucose metabolism based on a fasting glucose level \>6mmol/L and an HbA1c \>5.7% or as reviewed by study team; * Comorbidities or medications that would interfere with the participants ability to follow the study protocol or the quality of the data(e.g. diabetes, class III obesity, hormone therapy, another active cancer diagnosis); * Unable/unwilling to provide urine, breath and blood samples (e.g. oxygen tank, catheter, etc.); * Unable to eat the meals provided (i.e. receiving parenteral or enteral nutrition, severe allergies); * Substance dependent (e.g. alcohol, cigarettes, illicit drugs) and unable to follow study protocols.
Conditions Locally Advanced or Metastatic Breast Ca...
Phase PHASE2, PHASE3
Enrollment 254
Locations 22 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

This study evaluated the safety and efficacy of SPH4336 in combination with endocrine therapy in the treatment of locally advanced or metastatic breast cancer that progressed on CDK4/6 inhibitor combined with endocrine therapy.

Design

Study type: Interventional Phases: Phase2, Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: SPH4336 Tablets — SPH4336 Tablets :Administered by oral; Letrozole tablets:Administered by oral; Fulvestrant injection:Administered by intravenous infusion
  • Drug: SPH4336 Tablets Placebo — SPH4336 Tablets Placebo :Administered by oral; Letrozole tablets:Administered by oral; Fulvestrant injection:Administered by intravenous infusion

Primary Outcomes

  • Objective response rate (Approximately 3years)
  • Progression-free survival (PFS) (Approximately 3years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2, PHASE3
Status: Recruiting
Start Date: 2023-09-08
Completion: 2026-12-30
Eligibility
Age: 18 Years – 75 Years
Sex: FEMALE
Volunteers: false
Enrollment: 254 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd
Contact Information
Study Contact:
Shusen Wang
0086-020-87343811
wangshs@sysucc.org.cn
Shusen Wang
0086-020-87343811
wangshs@sysucc.org.cn
Affiliated Cancer Hospital, Sun Yat-sen University
Bin Yu
Liuzhou people's Hospital
Interventions
  • Drug: SPH4336 Tablets — SPH4336 Tablets :Administered by oral; Letrozole tablets:Administered by oral; Fulvestrant injection:Administered by intravenous infusion
  • Drug: SPH4336 Tablets Placebo — SPH4336 Tablets Placebo :Administered by oral; Letrozole tablets:Administered by oral; Fulvestrant injection:Administered by intravenous infusion
Study Locations (22 sites)
Affiliated Cancer Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510060 China
Liuzhou people's Hospital, Liuzhou, Guangxi 545026 China
Anyang Cancer Hospital, Anyang, He'nan 455001 China
The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, He'nan 450052 China
The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011 China
Harbin Medical University cancer Hospital, Harbin, Heilongjiang 150081 China
Xiangyang Cancer Hospital, Wuhan, Hubei 441021 China
Jiangsu Cancer Hospital, Nanjing, Jiangsu 210009 China
Jiangsu Province Hospital, Nanjing, Jiangsu 210029 China
Jilin Cancer Hospital, Changchun, Jilin 130012 China
Eligibility Criteria
Inclusion Criteria: 1. Patients who voluntarily participate in this study, completely understand this study, and voluntarily sign the informed consent form (ICF). 2. ECOG (Eastern Cooperative Oncology Group) performance status score of 0 or 1. 3. Life expectancy ≥ 3 months. 4. Patients with locally advanced or metastatic breast cancer who are unable to receive radical surgeries/other local therapies. 5. At least one measurable lesion. 6. Laboratory test results meet the relevant requirements for organ function. 7. Subjects who agree to take effective contraceptive measures. Exclusion Criteria: 1. Inflammatory breast cancer. 2. Patients unsuitable for endocrine therapy at the investigator's discretion. 3. History of other malignancies prior to the start of study treatment. 4. Patients with known metastases to central nervous system. 5. Taking anti-tumor traditional Chinese patent medicines at the time of signing the ICF. 6. Patients who underwent a surgery prior to the start of study treatment, and have not yet recovered from adverse reactions of the surgery. 7. Patients who participated in a clinical trial and received other investigational drugs before the start of study treatment. 8. Pregnant or lactating women. 9. History of myocardial infarction, unstable angina pectoris, severe arrhythmia, and symptomatic congestive heart failure before the start of study treatment; ≥ NYHA (New York Heart Association) Class II; mean QTc interval ≥ 470 ms before the start of study treatment; left ventricular ejection fraction ≤ 50% before the start of study treatment. 10. History of ischemic stroke or severe thromboembolic disease before the start of study treatment. 11. Hepatitis B surface antigen positive and HBV (Hepatitis B Virus) DNA \> 2,000 IU/mL or \> 104 copies/mL; HCV (Hepatitis C Virus) antibody positive and HCV RNA positive; or known HIV infection. 12. History of severe allergic diseases, history of severe drug allergies, or known allergy to any ingredient of the investigational product. 13. Presence of diseases or conditions that may impact drug administration or gastrointestinal absorption before the start of study treatment. 14. Presence of uncontrolled infections before the start of study treatment. 15. Known history of drug abuse, excessive drinking, or illegal drug use; history of confirmed neurological or mental disorders. 16. Presence of other diseases that the risks of receiving the study treatment outweigh its benefits, as determined by the investigator, or any other reason for which patients are ineligible for the study as assessed by the investigator.
Conditions Leptomeningeal Metastasis, Leptomeningea...
Phase PHASE2
Enrollment 30
Locations 11 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to evaluate the efficacy of tucatinib and capecitabine in combination with intrathecal trastuzumab on overall survival rate at 12 months in HER2-positive metastatic breast cancer (MBC) patients with proven leptomeningeal evolution and requiring intrathecal therapy.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Tucatinib Oral Tablet — 300 mg, twice daily
  • Drug: Capecitabine tablets — 1000 mg/m², twice daily on days 1-14 of each 21-day cycle
  • Drug: Trastuzumab Injection — Intrathecal by lumbar puncture or Ommaya Reservoir, 150 mg weekly

Primary Outcomes

  • overall survival rate at 12 months (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2023-12-18
Completion: 2027-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: UNICANCER
Collaborators: Seagen Inc.
Principal Investigators:
  • Louis LARROUQUERE (PRINCIPAL_INVESTIGATOR) - Centre Léon Bérard, Lyon
Contact Information
Study Contact:
Telma ROQUE, PhD
+33 (0) 1 80 50 12 92
t-roque@unicancer.fr
Jérôme LEMONNIER, PhD
+33 (0) 1 71 93 67 02
j-lemonnier@unicancer.fr
George EMILE, MD
Centre François Baclesse
Interventions
  • Drug: Tucatinib Oral Tablet — 300 mg, twice daily
  • Drug: Capecitabine tablets — 1000 mg/m², twice daily on days 1-14 of each 21-day cycle
  • Drug: Trastuzumab Injection — Intrathecal by lumbar puncture or Ommaya Reservoir, 150 mg weekly
Study Locations (11 sites)
Institut Bergonié, Bordeaux, 33000 France
Centre François Baclesse, Caen, 14000 France
Centre Jean Perrin, Clermont-Ferrand, 63011 France
Centre Georges-François Leclerc, Dijon, 21000 France
Centre Léon Bérard, Lyon, 69008 France
Institut régional du Cancer de Montpellier, Montpellier, 34298 France
Centre Antoine Lacassagne, Nice, 06189 France
Institut Jean Godinot, Reims, 51100 France
Centre Henri Becquerel, Rouen, 7600 France
Institut de cancérologie Strasbourg Europe - ICANS, Strasbourg, 67200 France
Eligibility Criteria
Inclusion Criteria: 1. Patient must have signed a written informed consent form prior to any trial specific procedures. When the patient is physically unable to give their written consent, a trusted person of their choice, independent from the investigator or the sponsor, can confirm in writing the patient's consent; 2. Patients ≥18 years old; 3. Histologically confirmed metastatic breast cancer; 4. Histologically confirmed HER2 positive breast cancer, with HER2 positive defined by in situ hybridization (ISH), immunohistochemistry (IHC), or fluorescence in situ hybridization (FISH) methodology; Note: HER2 testing should be performed preferably metastatic site; any estrogen and progesterone (ER/PR) status is allowed; 5. Proven leptomeningeal progression defined by linear leptomeningeal metastases on magnetic resonance imaging (MRI) or the presence of breast cancer cells in CSF (obtained within 28 days before inclusion ); 6. Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-2; 7. Life expectancy ≥2 months; 8. Stable dose of steroids for at least 5 days prior to registration; 9. If symptomatic brain or leptomeningeal metastasis, local treatment (surgery, radiation therapy) is allowed until 2 weeks before inclusion but should have been completed no more than 8 weeks before inclusion and with no clinical indication for immediate re-treatment with local therapy in the opinion of the investigator; 10. Adequate hematological function within 14 days before inclusion: Absolute neutrophil count (ANC) ≥1.5 x 10⁹/L; platelets count ≥100 x 10⁹/L; and hemoglobin ≥9.0 g/dL; 11. Adequate liver function within 14 days before inclusion: total bilirubin ≤1.5 ULN (unless documented Gilbert's syndrome); AST and ALT ≤2.5 ULN (≤5 ULN in the presence of liver metastases); 12. Normal renal function within 14 days before inclusion: estimated creatinine clearance ≥60 mL/min according to the Cockcroft-Gault formula; 13. Adequate cardiac function: * 12 Lead electrocardiograms (ECG) with normal tracing or non-clinically significant changes that do not require medical intervention * QT/QTc interval ≤470 msec for woman and ≤450 msec for men (mean of replicate values, correction per institutional standard) on the ECG at the screening visit and a normal kaliemia * Left ventricular ejection fraction (LVEF) ≥55% * No history of Torsades de Pointes or other symptomatic QTc abnormality 14. Resolution of all acute toxic effects of prior anti-cancer therapy or surgical procedures to National cancer institute-Common terminology criteria for adverse events (NCI-CTCAE) version 5.0 grade 1 or 0 to baseline (except alopecia or other toxicities not considered a safety risk for the patient at investigator's discretion); 15. Women of childbearing potential must have a negative pregnancy test (blood or urine test) within 14 days prior to inclusion; 16. Woman of childbearing potential and male patients must agree to use adequate contraception for the duration of trial participation and up to 7 months after completing treatment/therapy. Hormonal contraceptives such as birth control pills, patches, implants, or injections are not allowed in patients who are hormone receptor positive; 17. Patients affiliated to the social security system (or equivalent); 18. Patient must be willing and able to comply with the protocol for the duration of the trial including scheduled visits, treatment plan, laboratory tests, and examinations including follow-up. Exclusion Criteria: 1. Used of a strong cytochrome P450 (CYP)2C8 inhibitor within 5 half-lives of the inhibitor, or use of a strong CYP3A4 or CYP2C8 inducer within 5 days prior to first dose of study treatment. Use of sensitive CYP3A substrates should be avoided one week before enrollment and during study treatment; 2. Previous treatment with Tucatinib or Capecitabine; 3. Severe leukopenia, neutropenia, or thrombocytopena, severe hepatic impairment, severe renal impairment (creatinine clearance below 30mL/min) 4. Recent or concomitant treatment with brivudine ; 5. Any antiplatelet or curative anticoagulant treatment for blood coagulation disorders; 6. Severe pre-existing cerebrovascular dysfunction or pathology such as stroke and intra-cerebral hematoma or uncontrolled intracerebral hypertension induced by brain metastasis; 7. Ventriculoperitoneal or atrial shunt, except if the valve is equipped with an on-off device and that the patient's condition allows for to remain in the off position for 6 hours after each injection of trastuzumab; 8. Known history of testing positive for HIV or known acquired immunodeficiency syndrome; 9. Carriers of Hepatitis B or Hepatitis C or have other known chronic liver disease; 10. Uncontrolled hypertension; 11. Uncontrolled infection; 12. Severe dyspnea at rest due to complications of advanced malignancy or requiring supplementary oxygen therapy; 13. Pregnant or breast-feeding women; 14. Known prior severe hypersensitivity to tucatinib or compounds chemically or/and biologically similar or any component in its formulation; 15. Hypersensitivity to trastuzumab, murine proteins, or to any of the excipients in its formulation; 16. Known prior severe hypersensitivity to capecitabine or to any of the excipients or fluorouracil; 17. Known complete dihydropyrimidine dehydrogenase (DPD) deficiency (if applicable); 18. Inability to swallow tablets or significant gastrointestinal disease which would preclude the adequate oral absorption of medications; 19. Prior history of other malignancies other than study disease (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix) unless the patient has been free of the disease for at least 5 years; 20. Person deprived of their liberty or under protective custody or guardianship; 21. Participation in another therapeutic trial within the 30 days prior to treatment initiation; 22. Patients with any other disease or illness, which requires hospitalization or is incompatible with the trial treatment, are not eligible. Patients unwilling or unable to comply with trial obligations for geographic, social, or physical reasons, or who are unable to understand the purpose and procedures of the trial.